Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study.
Aydinok Y, Porter JB, Piga A, Elalfy M, El-Beshlawy A, Kilinç Y, Viprakasit V, Yesilipek A, Habr D, Quebe-Fehling E, Pennell DJ. Aydinok Y, et al. Among authors: kilinc y. Eur J Haematol. 2015 Sep;95(3):244-53. doi: 10.1111/ejh.12487. Epub 2015 Jan 8. Eur J Haematol. 2015. PMID: 25418187 Free article. Clinical Trial.
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.
Aydinok Y, Kattamis A, Cappellini MD, El-Beshlawy A, Origa R, Elalfy M, Kilinç Y, Perrotta S, Karakas Z, Viprakasit V, Habr D, Constantinovici N, Shen J, Porter JB; HYPERION Investigators. Aydinok Y, et al. Among authors: kilinc y. Blood. 2015 Jun 18;125(25):3868-77. doi: 10.1182/blood-2014-07-586677. Epub 2015 May 1. Blood. 2015. PMID: 25934475 Free PMC article. Clinical Trial.
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).
Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek A, Kilinç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y; CORDELIA study investigators. Pennell DJ, et al. Among authors: kilinc y. Blood. 2014 Mar 6;123(10):1447-54. doi: 10.1182/blood-2013-04-497842. Epub 2014 Jan 2. Blood. 2014. PMID: 24385534 Free PMC article. Clinical Trial.
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
Pennell DJ, Porter JB, Piga A, Lai YR, El-Beshlawy A, Elalfy M, Yesilipek A, Kilinç Y, Habr D, Musallam KM, Shen J, Aydinok Y; CORDELIA study investigators. Pennell DJ, et al. Among authors: kilinc y. Am J Hematol. 2015 Feb;90(2):91-6. doi: 10.1002/ajh.23876. Epub 2014 Nov 19. Am J Hematol. 2015. PMID: 25345697 Free article. Clinical Trial.
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Kwiatkowski JL, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Alshehri A, Kanter J, Inusa B, Adly AAM, Williams S, Kilinc Y, Lee D, Tricta F, Elalfy MS. Kwiatkowski JL, et al. Among authors: kilinc y. Blood Adv. 2022 Feb 22;6(4):1243-1254. doi: 10.1182/bloodadvances.2021004938. Blood Adv. 2022. PMID: 34847228 Free PMC article. Clinical Trial.
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.
Elalfy MS, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Kanter J, Inusa B, Adly AAM, Williams S, Kilinc Y, Lee D, Fradette C, Rozova A, Temin NT, Tricta F, Kwiatkowski JL. Elalfy MS, et al. Among authors: kilinc y. Blood Adv. 2023 Feb 28;7(4):611-619. doi: 10.1182/bloodadvances.2021006778. Blood Adv. 2023. PMID: 36018224 Free PMC article. Clinical Trial.
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. Cappellini MD, et al. Among authors: kilinc y. Blood. 2006 May 1;107(9):3455-62. doi: 10.1182/blood-2005-08-3430. Epub 2005 Dec 13. Blood. 2006. PMID: 16352812 Free article. Clinical Trial.
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y. Cappellini MD, et al. Among authors: kilinc y. Blood. 2011 Jul 28;118(4):884-93. doi: 10.1182/blood-2010-11-316646. Epub 2011 May 31. Blood. 2011. PMID: 21628399 Free article. Clinical Trial.
A National Registry of Thalassemia in Turkey: Demographic and Disease Characteristics of Patients, Achievements, and Challenges in Prevention.
Aydınok Y, Oymak Y, Atabay B, Aydoğan G, Yeşilipek A, Ünal S, Kılınç Y, Oflaz B, Akın M, Vergin C, Sezgin Evim M, Çalışkan Ü, Ünal Ş, Bay A, Kazancı E, İleri T, Atay D, Patıroğlu T, Kahraman S, Söker M, Akcan M, Akdeniz A, Büyükavcı M, Alanoğlu G, Bör Ö, Soyer N, Özdemir Karadaş N, Uysalol E, Türker M, Akçay A, Ocak S, Güneş AM, Tokgöz H, Ünal E, Tiftik N, Karakaş Z. Aydınok Y, et al. Among authors: kilinc y. Turk J Haematol. 2018 Mar 1;35(1):12-18. doi: 10.4274/tjh.2017.0039. Epub 2017 Apr 13. Turk J Haematol. 2018. PMID: 28404539 Free PMC article.
National thalassemia prevention campaign: the talotır project.
Canatan D, Aydınok Y, Kılınç Y, Karakaş Z, Saşmaz I, Apak H, Sarper N. Canatan D, et al. Among authors: kilinc y. Turk J Haematol. 2013 Mar;30(1):91-2. doi: 10.4274/tjh.2012.0121. Epub 2013 Mar 5. Turk J Haematol. 2013. PMID: 24385764 Free PMC article. No abstract available.
123 results